SCHEDULE: Morgan Stanley Discloses 6.3% Stake in AnaptysBio

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have disclosed beneficial ownership of 6.3% of AnaptysBio, Inc.'s common stock.

Summary

• Morgan Stanley, a Delaware-based holding company, reported beneficial ownership of 1,845,002 shares of AnaptysBio, Inc. common stock, representing 6.3% of the class.
• Morgan Stanley Capital Services LLC, a wholly-owned broker-dealer subsidiary of Morgan Stanley, separately reported beneficial ownership of 1,525,502 shares, representing 5.2% of the class.
• The shares are held in the ordinary course of business and were not acquired for the purpose of changing or influencing the control of AnaptysBio, Inc.
• Both entities share voting and dispositive power over their respective reported holdings.
• The filing was made pursuant to Rule 13d-1(b) of the Securities Exchange Act of 1934.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership, inherently neutral in sentiment regarding the issuer's performance or outlook.

Positives

• NA

Negatives

• NA

Risks

• The filing certifies that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, nor in connection with any transaction having that purpose or effect.

Future Outlook

NA

Industry Context

This filing indicates a significant institutional investment in AnaptysBio, Inc., a biotechnology company. Such disclosures are common for large financial institutions like Morgan Stanley, which manage substantial portfolios across various industries, including biotech.

Related Party Transactions

• Morgan Stanley Capital Services LLC, one of the reporting persons, is a wholly-owned subsidiary of Morgan Stanley, the other reporting person. The securities reported by Morgan Stanley are owned or deemed beneficially owned by Morgan Stanley Capital Services LLC.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional holder like Morgan Stanley can be viewed positively, indicating institutional confidence or interest in AnaptysBio. It also provides transparency regarding major ownership stakes.
• Management: Awareness of a large institutional holder may influence strategic decisions, though the filing explicitly states the holding is not for control purposes.

Key Dates

Keywords

AnaptysBio, Morgan Stanley, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotechnology, SEC Filing